CAR-engineered neutrophils derived from induced pluripotent stem cells: a new frontier in cellular immunotherapy.
Scientists propose using engineered immune cells grown from stem cells as an alternative to CAR-T therapy, potentially solving problems with cell availability and lifespan.
This review surveys the emerging field of CAR-neutrophil therapy derived from induced pluripotent stem cells, outlining the scientific rationale for using neutrophils as CAR carriers and the practical advantages and obstacles relative to CAR-T cells. iPSC technology is proposed as the scalable source to overcome the key obstacles of short neutrophil lifespan and limited ex vivo proliferation.
What the study was
- Study design
- Narrative review
- Category
- Drug Development
- Maturity
- Exploratory
- Journal
- Clinical and Translational Oncology
Why it surfaced
iPSC-CAR-neutrophil is a novel platform concept with potential advantages in solid tumor penetration; review article only, no clinical data yet.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.